Open AccessContinued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
Author(s) -
Piotrowska Zofia,
Sequist Lecia V.
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2015-0370
Subject(s) - medicine , chemotherapy , lung cancer , oncology , egfr inhibitors , epidermal growth factor receptor , intensive care medicine , cancer
A growing body of evidence suggests that continuing EGFR inhibitors when switching to chemotherapy may not be the right choice for all patients. Nevertheless, a review of recent data about postprogression therapy for patients with EGFR‐mutant lung cancer reveals some important caveats that must be considered when choosing the optimal treatment for patients who have progressed on their initial EGFR inhibitor.